D.A. Davidson & CO. Has $3.30 Million Holdings in Eli Lilly And Co (NYSE:LLY)

Share on StockTwits

D.A. Davidson & CO. lifted its holdings in Eli Lilly And Co (NYSE:LLY) by 9.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,512 shares of the company’s stock after purchasing an additional 2,529 shares during the period. D.A. Davidson & CO.’s holdings in Eli Lilly And Co were worth $3,300,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in LLY. Nuveen Asset Management LLC lifted its stake in shares of Eli Lilly And Co by 20,030.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock valued at $804,983,000 after purchasing an additional 7,229,751 shares during the last quarter. Renaissance Technologies LLC lifted its position in Eli Lilly And Co by 218.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,308,601 shares of the company’s stock worth $255,770,000 after acquiring an additional 1,583,947 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC lifted its position in Eli Lilly And Co by 5,612.3% during the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,591,396 shares of the company’s stock worth $176,311,000 after acquiring an additional 1,563,537 shares during the last quarter. AQR Capital Management LLC lifted its position in Eli Lilly And Co by 53.3% during the 2nd quarter. AQR Capital Management LLC now owns 4,335,702 shares of the company’s stock worth $480,048,000 after acquiring an additional 1,507,050 shares during the last quarter. Finally, BlackRock Inc. lifted its position in Eli Lilly And Co by 1.5% during the 2nd quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock worth $6,866,670,000 after acquiring an additional 898,845 shares during the last quarter. 77.37% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Stephen F. Fry sold 9,452 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the transaction, the senior vice president now owns 100,211 shares in the company, valued at approximately $11,524,265. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 4,500 shares of the business’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $117.00, for a total transaction of $526,500.00. Following the transaction, the senior vice president now owns 33,806 shares in the company, valued at approximately $3,955,302. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 8,405 shares of company stock worth $909,004 and have sold 614,473 shares worth $70,558,302. Insiders own 0.11% of the company’s stock.

Eli Lilly And Co stock traded down $1.10 on Thursday, reaching $111.69. 49,900 shares of the stock were exchanged, compared to its average volume of 3,439,353. The stock has a market cap of $108.30 billion, a PE ratio of 20.11, a PEG ratio of 1.85 and a beta of 0.16. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 4.09. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $132.13. The firm has a fifty day moving average price of $110.43 and a two-hundred day moving average price of $112.61.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The company had revenue of $5.48 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the previous year, the firm posted $1.39 EPS. The business’s revenue was up 3.2% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly And Co will post 5.79 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.645 per share. The ex-dividend date is Thursday, November 14th. This represents a $2.58 annualized dividend and a dividend yield of 2.31%. Eli Lilly And Co’s payout ratio is 46.49%.

A number of research firms have weighed in on LLY. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a research report on Friday, November 8th. Bank of America began coverage on shares of Eli Lilly And Co in a research report on Wednesday, October 16th. They set a “buy” rating and a $133.00 target price for the company. Finally, UBS Group cut their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday, October 17th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $130.03.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Dividend Yield

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

First Bancorp  Rating Increased to Buy at Zacks Investment Research
First Bancorp Rating Increased to Buy at Zacks Investment Research
Adaptimmune Therapeutics PLC –  Short Interest Up 11.5% in November
Adaptimmune Therapeutics PLC – Short Interest Up 11.5% in November
Catchmark Timber Trust  Rating Increased to Buy at Zacks Investment Research
Catchmark Timber Trust Rating Increased to Buy at Zacks Investment Research
Ciena  PT Raised to $48.00 at Dougherty & Co
Ciena PT Raised to $48.00 at Dougherty & Co
Short Interest in AC Immune SA  Decreases By 11.9%
Short Interest in AC Immune SA Decreases By 11.9%
Short Interest in Audioeye  Inc  Decreases By 11.1%
Short Interest in Audioeye Inc Decreases By 11.1%


© 2006-2019 Ticker Report